Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.59 |
| ▸ | GLA | P06280 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10076141 | 0.87 | ALDH1A1 (0.62) | POLBNPSR1ALDH1A1GLAPKM | |
| SCHEMBL10076159 | 0.82 | ALDH1A1 (0.52) | POLBNPSR1ALDH1A1GLAPKM | |
| SCHEMBL10076130 | 0.78 | ALDH1A1 (0.58) | POLBNPSR1ALDH1A1GLAHTT | |
| SCHEMBL10076137 | 0.78 | ALDH1A1 (0.66) | POLBNPSR1ALDH1A1GLAHSD17B10 | |
| SCHEMBL1911513 | 0.76 | ALDH1A1 (0.68) | POLBNPSR1ALDH1A1PKMLMNA | |
| SCHEMBL16026437 | 0.75 | ALDH1A1 (0.83) | POLBNPSR1ALDH1A1PKMHSD17B10 | |
| SCHEMBL10076145 | 0.73 | MEN1 (0.46) | ALDH1A1PKMHTTSMN1; SMN2TSHR | |
| SCHEMBL14350981 | 0.73 | NPSR1 (0.69) | POLBNPSR1ALDH1A1GLAHTT | |
| SCHEMBL13612640 | 0.73 | ALDH1A1 (0.72) | POLBNPSR1ALDH1A1GLAPKM | |
| SCHEMBL13804475 | 0.71 | ALDH1A1 (0.71) | POLBNPSR1ALDH1A1HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093231-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | TELIK, INC. | 2008-02-14 | — | — | US | disclosed |
| US-7262182-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | MTAP, TYMP, PHOSPHO1 | POLB 3723/4885NPSR1 2892/4885ALDH1A1 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.